News

MITA Comments on CMS Proposed Rescission of MCIT Program

The Medical Imaging & Technology Alliance (MITA) in a comment letter to Centers for Medicare & Medicaid Services (CMS), expressed disappointment with the agencys proposal to withdraw the previously finalized Medicare Coverage of Innovative Technology (MCIT) rule and urged CMS to work with industry, health care providers, patients and others to improve and expedite the path from U.S. Food & Drug Administration (FDA) marketing authorization to CMS coverage.

Mon Oct 25 2021By MedWrench News Team

“Medical technology developers need to have access to expedient, transparent, and predictable pathways to bring innovative products to Medicare beneficiaries,” the letter noted. It continued by highlighting MITA comments requesting that the MCIT program be expanded beyond just “Breakthrough” technologies, given that not all innovative products earn this designation.

In January 2021, CMS published a final rule called The Medicare Coverage of Innovative Technology and Definition of ‘Reasonable and Necessary’ (MCIT/R&N). The MCIT program would have granted expedited Medicare coverage for up to four years for any FDA-designated “Breakthrough” device once the device received marketing authorization.

The full MITA comments are available here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Please review our Privacy Policy for more details.
I Agree